Genetic Total Liab from 2010 to 2024
| GENE Stock | USD 0.77 0.00 0.00% |
Total Liabilities | First Reported 2003-06-30 | Previous Quarter 4.4 M | Current Value 4.4 M | Quarterly Volatility 1.6 M |
Check Genetic Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genetic Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 508.1 K, Interest Expense of 83.6 K or Total Revenue of 5.3 M, as well as many indicators such as Price To Sales Ratio of 1.27, Dividend Yield of 0.0 or PTB Ratio of 5.31. Genetic financial statements analysis is a perfect complement when working with Genetic Technologies Valuation or Volatility modules.
Genetic | Total Liab |
Latest Genetic Technologies' Total Liab Growth Pattern
Below is the plot of the Total Liab of Genetic Technologies over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Genetic Technologies' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genetic Technologies' overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Genetic Total Liab Regression Statistics
| Arithmetic Mean | 2,484,426 | |
| Geometric Mean | 2,230,325 | |
| Coefficient Of Variation | 50.24 | |
| Mean Deviation | 1,012,582 | |
| Median | 2,039,109 | |
| Standard Deviation | 1,248,157 | |
| Sample Variance | 1.6T | |
| Range | 3.6M | |
| R-Value | 0.34 | |
| Mean Square Error | 1.5T | |
| R-Squared | 0.12 | |
| Significance | 0.21 | |
| Slope | 94,956 | |
| Total Sum of Squares | 21.8T |
Genetic Total Liab History
About Genetic Technologies Financial Statements
Genetic Technologies stakeholders use historical fundamental indicators, such as Genetic Technologies' Total Liab, to determine how well the company is positioned to perform in the future. Although Genetic Technologies investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genetic Technologies' assets and liabilities are reflected in the revenues and expenses on Genetic Technologies' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genetic Technologies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 4.4 M | 2.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genetic Technologies is a strong investment it is important to analyze Genetic Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Genetic Technologies' future performance. For an informed investment choice regarding Genetic Stock, refer to the following important reports:Check out the analysis of Genetic Technologies Correlation against competitors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.02) | Revenue Per Share 2.19 | Quarterly Revenue Growth (0.11) | Return On Assets (0.63) | Return On Equity (1.85) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.